Validating the mode of action of ergosterol peroxide as a selective breast cancer inhibitor
验证过氧化麦角甾醇作为选择性乳腺癌抑制剂的作用方式
基本信息
- 批准号:10610422
- 负责人:
- 金额:$ 11.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-04-15 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:4T1AddressAffectAfrican AmericanAminoacyl-tRNA hydrolaseAnkyrin RepeatApoptosisBiologicalBiological AssayBiological AvailabilityBiomedical ResearchBiophysicsBreast Cancer CellBreast Cancer ModelBreast Cancer PatientBreast Cancer TreatmentCell DeathCell Death InductionCell LineCell modelCellsCellular AssayCessation of lifeChemicalsCholesterolCholesterol HomeostasisClinicClinical ResearchClustered Regularly Interspaced Short Palindromic RepeatsComplexCytosolDataDependenceDevelopmentDiagnosisDiseaseDoseDoxycyclineDrug toxicityERBB2 geneEarly DiagnosisEnvironmentEnzymesErgosterolExcisionExtravasationFemaleFutureGenesGoalsHispanic AmericansHomeostasisImpairmentIn complete remissionKnowledgeLeadLigationMCF10A cellsMalignant NeoplasmsMembraneMitochondriaMitochondrial ProteinsModalityModelingMusNatural ProductsNormal CellNormal tissue morphologyOxidation-ReductionOxidative StressPathway interactionsPatient-derived xenograft models of breast cancerPatientsPeroxidesPrognosisPropertyProtacProteinsPuerto RicoRecurrent diseaseResearchResistanceSafetyScientistSterolsStructureStudentsSubstrate SpecificitySurvival RateSystemTestingTherapeuticTherapeutic AgentsToxic effectTumor VolumeUbiquitinUbiquitinationUnited StatesWomanXenograft procedureZinc Fingersaggressive breast canceranti-cancer therapeuticantiproliferative agentscancer cellcancer subtypeschemotherapyclinically relevantcofactorefficacy evaluationefficacy testingfungusimprovedin vivoin vivo Modelinhibitormalignant breast neoplasmmisfolded proteinmitochondrial dysfunctionmortalitymouse modelmulticatalytic endopeptidase complexneoplastic cellnovelpharmacokinetics and pharmacodynamicspharmacologicpre-clinicalprotein aggregationprotein complexpublic health relevancestemstudent participationtargeted treatmenttriple-negative invasive breast carcinomatumor progressionunderrepresented minority studentuptakevalosin-containing proteinwomen of color
项目摘要
PROJECT SUMMARY
Triple Negative Breast Cancer (TNBC) is an aggressive and lethal breast cancer subtype more commonly
diagnosed on younger (<40y) women of color (Hispanics and African American), who are more likely to have
disease recurrence and who have an overall shorter survival. Furthermore, additional limitations (i.e. drug
toxicity, and therapy resistance) persist in the clinic for TNBC patients. Thus, a critical need exists to discover
more desirable targeted therapeutic modalities that selectively target TNBC tumor cells while leaving normal
cells unaffected, enhancing a complete response and reducing TNBC-associated mortality rates. Accordingly,
our goal is to reduce BC mortality by identifying unique vulnerabilities of TNBC that can be exploited through the
development of selective therapeutic agents. We recently identified the natural product ergosterol peroxide a
steroidal compound found in fungi, as a potent antiproliferative agent against TNBC cell models with little to no
effect on noncancerous cells. We demonstrated that EP is more potent towards TNBC than HER2-positive
models. EP induces ROS and apoptosis in TNBC cells and reduces tumor volume in TNBC models in vivo.
However, EP’s mode of action (MOA) remains to be defined. Extended periods of oxidative stress in the
mitochondria lead to accumulation of damaged proteins, which are normally removed by ubiquitination via the
VCP/ANKZF1 pathway. We have synthesized EP in gram scale and show that EP accumulates in the cytosol
and affects VCP and ANKZF1 interactions, raising the possibility that the VCP/ANKZF1 complex is targeted
during its assembly prior to arriving to the mitochondria. Thus, taking advantage of TNBC’s dependency on sterol
uptake, removal of misfolded proteins and altered redox homeostasis, we propose that EP serves as a
VCP/ANKZF1 complex protein-protein inhibitor (PPI). We hypothesize that EP targets the VCP/ANKZF1
complex, impairing the ability of cancer cells to clear damaged proteins and causing mitochondria dysfunction to
induce TNBC cell death. To test the hypothesis we will identify the mechanism by which EP targets the
VCP/ANKZF1 complex in TNBC models using biophysical assays and synthesized EP-probes (Aim 1). The
results from this Aim will validate that targeting VCP/ANKZF1 complex induces increases misfolded and
aggregated proteins, which lead to cancer cell death. We will determine the efficacy of EP using syngeneic
models injected with doxycycline inducible ANKZF1 silenced cells, and in TNBC PDXs. EP safety and bio-
availability will also be determined and studied by MTD and PK/PD (Aim 2). The result of this aim will provide
data needed for the next step towards the translational development of EP. Student participation in this
hypothesis-driven research will improve the pipeline for URM students in biomedical research and lead to
improved BC treatment.
项目概要
三阴性乳腺癌 (TNBC) 是一种更常见的侵袭性和致命性乳腺癌亚型
诊断为年轻(<40 岁)有色人种女性(西班牙裔和非裔美国人),她们更有可能患有
疾病复发和总生存期较短的人。
因此,迫切需要发现 TNBC 患者的临床症状。
更理想的靶向治疗方式,选择性靶向 TNBC 肿瘤细胞,同时保留正常细胞
细胞不受影响,增强完全反应并降低 TNBC 相关死亡率。
我们的目标是通过识别 TNBC 的独特漏洞来降低 BC 死亡率,这些漏洞可以通过
我们最近发现了天然产物过氧化麦角甾醇a。
在真菌中发现的类固醇化合物,作为针对 TNBC 细胞模型的有效抗增殖剂,几乎没有作用
我们证明 EP 对 TNBC 比 HER2 阳性细胞更有效。
EP 诱导 TNBC 细胞中的 ROS 和细胞凋亡,并减少体内 TNBC 模型中的肿瘤体积。
然而,EP 的作用模式 (MOA) 仍有待确定。
线粒体导致受损蛋白质的积累,这些蛋白质通常通过泛素化通过
VCP/ANKZF1 途径我们合成了克级的 EP,并表明 EP 在细胞质中积累。
并影响 VCP 和 ANKZF1 相互作用,增加了 VCP/ANKZF1 复合物被靶向的可能性
因此,利用 TNBC 对甾醇的依赖性。
摄取、去除错误折叠的蛋白质和改变氧化还原稳态,我们建议 EP 作为
我们发现 EP 靶向 VCP/ANKZF1。
复杂,损害癌细胞清除受损蛋白质的能力并导致线粒体功能障碍
诱导 TNBC 细胞死亡 为了检验这一假设,我们将确定 EP 靶向的机制。
使用生物物理测定和合成的 EP 探针在 TNBC 模型中形成 VCP/ANKZF1 复合物(目标 1)。
该目的的结果将验证靶向 VCP/ANKZF1 复合物会诱导错误折叠和
聚集的蛋白质,导致癌细胞死亡,我们将使用同基因确定 EP 的功效。
注射多西环素诱导的 ANKZF1 沉默细胞的模型,以及 TNBC PDX 的安全性和生物性。
可用性也将由 MTD 和 PK/PD 确定和研究(目标 2)。
学生参与下一步的转化发展所需的数据。
假设驱动的研究将改善 URM 学生在生物医学研究方面的渠道,并导致
改善 BC 治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michelle M Martínez其他文献
Pharmacological zinc and phytase supplementation enhance metallothionein mRNA abundance and protein concentration in newly weaned pigs.
药理学锌和植酸酶补充剂可增强刚断奶仔猪的金属硫蛋白 mRNA 丰度和蛋白质浓度。
- DOI:
- 发表时间:
2004 - 期刊:
- 影响因子:0
- 作者:
Michelle M Martínez;G. Hill;J. Link;N. Raney;R. Tempelman;C. Ernst - 通讯作者:
C. Ernst
Michelle M Martínez的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michelle M Martínez', 18)}}的其他基金
Validating the mode of action of ergosterol peroxide as a selective breast cancer inhibitor
验证过氧化麦角甾醇作为选择性乳腺癌抑制剂的作用方式
- 批准号:
10411072 - 财政年份:2022
- 资助金额:
$ 11.7万 - 项目类别:
INVESTIGATION OF REISHI AS A NATURAL THERAPEUTIC FOR INFLAMMATORY BREAST CANCER
灵芝作为炎性乳腺癌天然疗法的研究
- 批准号:
8357105 - 财政年份:2011
- 资助金额:
$ 11.7万 - 项目类别:
INVESTIGATION OF REISHI AS A NATURAL THERAPEUTIC FOR INFLAMMATORY BREAST CANCER
灵芝作为炎性乳腺癌天然疗法的研究
- 批准号:
8166209 - 财政年份:2010
- 资助金额:
$ 11.7万 - 项目类别:
INVESTIGATION OF REISHI AS A NATURAL THERAPEUTIC FOR INFLAMMATORY BREAST CANCER
灵芝作为炎性乳腺癌天然疗法的研究
- 批准号:
8573333 - 财政年份:1997
- 资助金额:
$ 11.7万 - 项目类别:
INVESTIGATION OF REISHI AS A NATURAL THERAPEUTIC FOR INFLAMMATORY BREAST CANCER
灵芝作为炎性乳腺癌天然疗法的研究
- 批准号:
8573407 - 财政年份:
- 资助金额:
$ 11.7万 - 项目类别:
相似国自然基金
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
相似海外基金
The regulation of cancer and aging by methionine
蛋氨酸对癌症和衰老的调节
- 批准号:
10750559 - 财政年份:2023
- 资助金额:
$ 11.7万 - 项目类别:
Validating the mode of action of ergosterol peroxide as a selective breast cancer inhibitor
验证过氧化麦角甾醇作为选择性乳腺癌抑制剂的作用方式
- 批准号:
10411072 - 财政年份:2022
- 资助金额:
$ 11.7万 - 项目类别:
Impact of mtDNA Mutations and Transfer on Tumor Growth Dynamics
mtDNA 突变和转移对肿瘤生长动态的影响
- 批准号:
10155111 - 财政年份:2021
- 资助金额:
$ 11.7万 - 项目类别:
Impact of mtDNA Mutations and Transfer on Tumor Growth Dynamics
mtDNA 突变和转移对肿瘤生长动态的影响
- 批准号:
10439441 - 财政年份:2021
- 资助金额:
$ 11.7万 - 项目类别:
Overcoming stress driven suppression of the anti-tumor immune response in cancer - understanding the MDSC piece of the puzzle
克服癌症中压力驱动的抗肿瘤免疫反应抑制——了解 MDSC 的难题
- 批准号:
10065427 - 财政年份:2020
- 资助金额:
$ 11.7万 - 项目类别: